ArticleBMC infectious diseases2025
Computational development of multi-epitope vaccine to induce adaptive immunity against multi-drug resistant Prevotella intermedia.
Article in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- mRNA vaccine design targeting Merkel cell polyomavirus for immunotherapy of Merkel cell carcinoma.Scientific reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Prevotella intermedia is a gram-negative, anaerobic, multidrug-resistant bacterium known to cause oral infections. Given its clinical significance as an opportunistic pathogen, developing effective preventive and therapeutic measures is crucial. This study employed an integrated approach, combining subtractive proteomics and immunoinformatics, to identify novel therapeutic targets. We analyzed the core genome of P. intermedia, revealing five essential proteins as potential drug targets and three as potential candidates for a vaccine. The selected vaccine candidate proteins underwent additional evaluation to determine their immunogenic epitopes (B-cell, MHC-I, and MHC-II) and the design multi-epitope vaccine incorporating suitable linkers and adjuvants. Structural validation, including the identification of globular regions and post-translational modifications (PTMs), was performed. Molecular docking with the TLR4 receptor demonstrated strong interactions, and molecular dynamics (MD) simulations, dynamic cross-correlation matrix (DCCM) analysis, binding free energy calculations, and principal component analysis (PCA) confirmed stable binding between the vaccine prototypes and TLR4. Among the four proposed vaccines, we identified HBHA-PiMEV, L7/12-PiMEV, and GMCSF-PiMEV as most effective, with sustained interactions to human immune receptors and docking scores of -1110·2cal/mol, -1016·1 kcal/mol, and -1149·6 kcal/mol, as well as 15, 27, and 16 hydrogen bonds respectively. Based on different evaluation parameters, HBHA-PiMEV was identified as the most effective vaccine construct. Additionally, the novel drug targets were annotated for their roles in key biological processes, underscoring their therapeutic value. In summary, our investigation identified novel therapeutic targets and designed potent vaccine constructs against P. intermedia for further experimental validation to combat this multidrug-resistant pathogen.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.